These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 33619137)
1. Leukaemic relapse of anaplastic large cell lymphoma, ALK negative. Karki NR; Badin K; Savage N; Bryan L BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33619137 [TBL] [Abstract][Full Text] [Related]
2. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL. Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y Front Immunol; 2024; 15():1346001. PubMed ID: 38375471 [TBL] [Abstract][Full Text] [Related]
3. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. Oregel KZ; Everett E; Zhang X; Nagaraj G Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026 [TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Foyil KV; Bartlett NL Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951 [TBL] [Abstract][Full Text] [Related]
5. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management. Shustov A; Soma L Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216 [TBL] [Abstract][Full Text] [Related]
6. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. Eyre TA; Khan D; Hall GW; Collins GP Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435 [TBL] [Abstract][Full Text] [Related]
8. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population. Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811 [TBL] [Abstract][Full Text] [Related]
9. Leukaemic Presentation of Small-Cell Alk-Positive Anaplastic Large Cell Lymphoma in a Young Woman-Report of a Case with 9-Year Survival. Santonja C; Morillo-Giles D; Prieto-Pareja E; Soto-de Ozaeta C; Serrano-Del Castillo C; Salgado-Sánchez R; Yi-Shi AW; Manso R; Rodríguez-Pinilla SM Medicina (Kaunas); 2023 Sep; 59(9):. PubMed ID: 37763746 [TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents. Rigaud C; Knörr F; Brugières L; Woessmann W Best Pract Res Clin Haematol; 2023 Mar; 36(1):101444. PubMed ID: 36907641 [TBL] [Abstract][Full Text] [Related]
11. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review. Noguchi K; Ikawa Y Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136278 [TBL] [Abstract][Full Text] [Related]
12. The biology and management of systemic anaplastic large cell lymphoma. Hapgood G; Savage KJ Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285 [TBL] [Abstract][Full Text] [Related]
13. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report. Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688 [TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Lowe EJ; Reilly AF; Lim MS; Gross TG; Saguilig L; Barkauskas DA; Wu R; Alexander S; Bollard CM Blood; 2021 Jul; 137(26):3595-3603. PubMed ID: 33684925 [TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022 [TBL] [Abstract][Full Text] [Related]
16. ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient. Pulitzer M; Ogunrinade O; Lin O; Steinherz P J Cutan Pathol; 2015 Mar; 42(3):182-187. PubMed ID: 25404214 [TBL] [Abstract][Full Text] [Related]
17. Anaplastic large cell lymphoma: a single institution experience from India. Lakshmaiah KC; Guruprasad B; Shah A; Kavitha S; Abraham LJ; Govindbabu K; Aruna Kumari BS; Appaji L J Cancer Res Ther; 2013; 9(4):649-52. PubMed ID: 24518711 [TBL] [Abstract][Full Text] [Related]
18. [Spontaneous remission of relapsed skin lesions of ALK-positive anaplastic large cell lymphoma after autologous stem cell transplantation]. Yamazaki R; Koda Y; Abe R; Sakurai M; Kikuchi T; Kato J; Ouchi T; Mikami S; Mori T Rinsho Ketsueki; 2021; 62(1):25-29. PubMed ID: 33551421 [TBL] [Abstract][Full Text] [Related]
19. Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation. Miyazaki M; Ichikawa S; Onishi Y; Fukuhara N; Furukawa E; Onodera K; Yokoyama H; Ichinohasama R; Harigae H J Clin Exp Hematop; 2022 Sep; 62(3):164-168. PubMed ID: 35732409 [TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin in anaplastic large cell lymphoma. Skarbnik AP; Smith MR Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]